Handelsbanken Fonder AB Invests $1.49 Million in Dianthus Therapeutics, Inc. $DNTH

Handelsbanken Fonder AB bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 15,300 shares of the company’s stock, valued at approximately $1,491,000.

Several other hedge funds and other institutional investors have also bought and sold shares of DNTH. Vestal Point Capital LP boosted its position in Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after acquiring an additional 2,503,311 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after acquiring an additional 406,254 shares in the last quarter. TCG Crossover Management LLC lifted its stake in shares of Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after purchasing an additional 175,000 shares during the period. Finally, State Street Corp boosted its position in shares of Dianthus Therapeutics by 124.7% during the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after purchasing an additional 836,571 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. HC Wainwright raised their price objective on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $124.27.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, Director Anne Mcgeorge sold 7,750 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the transaction, the director directly owned 1,250 shares of the company’s stock, valued at approximately $136,262.50. This trade represents a 86.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the sale, the executive vice president directly owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 284,306 shares of company stock valued at $29,289,369 over the last three months. 3.02% of the stock is currently owned by company insiders.

Dianthus Therapeutics Stock Performance

DNTH stock opened at $115.54 on Wednesday. The stock’s 50 day simple moving average is $98.77 and its 200 day simple moving average is $83.98. Dianthus Therapeutics, Inc. has a fifty-two week low of $20.69 and a fifty-two week high of $116.89. The company has a market cap of $6.32 billion, a P/E ratio of -27.84 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Equities analysts predict that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.